<DOC>
	<DOC>NCT02837575</DOC>
	<brief_summary>The purpose of this trial is to evaluate the safety and efficacy of a therapeutic DNA vaccine in adults with symptomatic herpes simplex virus type 2 (i.e., genital herpes).</brief_summary>
	<brief_title>Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine</brief_title>
	<detailed_description>To evaluate the safety and efficacy of 4 doses of VCL-HB01, a therapeutic HSV plasmid DNA vaccine formulated with VaxfectinÂ® in HSV-2-seropositive adults with a reported history of symptomatic genital herpes for at least one year.</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Herpes Genitalis</mesh_term>
	<criteria>HSV2 seropositive A minimum of 1 year of reported history of genital herpes with recurrences. History of receiving an investigational HSV vaccine Chronic illness for which a subject's immune system is suspected to be impaired or altered, such as cancer, autoimmune conditions, or diabetes Pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HSV-2</keyword>
	<keyword>Genital Herpes</keyword>
	<keyword>Herpes</keyword>
	<keyword>Herpes Simplex Virus, Type 2</keyword>
</DOC>